Deciphera Pharmaceuticals Inc (DCPH)
25.46
+0.02
(+0.06%)
USD |
NASDAQ |
May 17, 16:00
25.46
0.00 (0.00%)
After-Hours: 20:00
Deciphera Pharmaceuticals Cash from Financing (TTM): 17.84M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 17.84M |
December 31, 2023 | 152.00M |
September 30, 2023 | 151.59M |
June 30, 2023 | 136.21M |
March 31, 2023 | 299.60M |
December 31, 2022 | 164.99M |
September 30, 2022 | 166.49M |
June 30, 2022 | 167.99M |
March 31, 2022 | 5.449M |
December 31, 2021 | 14.89M |
September 30, 2021 | 40.70M |
June 30, 2021 | 42.23M |
March 31, 2021 | 44.93M |
Date | Value |
---|---|
December 31, 2020 | 226.80M |
September 30, 2020 | 199.77M |
June 30, 2020 | 631.02M |
March 31, 2020 | 626.65M |
December 31, 2019 | 436.37M |
September 30, 2019 | 435.67M |
June 30, 2019 | 0.693M |
March 31, 2019 | 187.14M |
December 31, 2018 | 185.99M |
September 30, 2018 | 313.42M |
June 30, 2018 | 311.14M |
March 31, 2018 | 176.42M |
December 31, 2017 | 176.40M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.693M
Minimum
Jun 2019
631.02M
Maximum
Jun 2020
198.10M
Average
158.50M
Median
Cash from Financing (TTM) Benchmarks
Bristol-Myers Squibb Co | 8.278B |
Dynavax Technologies Corp | 0.273M |
Gilead Sciences Inc | -5.08B |
Esperion Therapeutics Inc | 91.57M |
SINTX Technologies Inc | 5.551M |